去年，Rockwell Medical Inc表现最佳的业务板块Concentrate Products实现营收68.93M美元。United States的营收贡献最高，去年达到60.36M美元。最近一个季度，截至2026-06-30，Rockwell Medical Inc表现最佳的业务板块Concentrate Products实现营收17.78M美元。United States的营收贡献最高，达到15.13M美元。

业务

营业收入

占比

年报

年报

单季报

Concentrate Products

Drug Products

Concentrate Products –Product Sales – Point-in-time Over time

Concentrate Products –License Fee – Point-in-time

Drug Revenues-License Fee – Over time

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

Concentrate Products

68.93M(99.53%)

101.44M(99.95%)

81.27M(97.20%)

71.65M(98.41%)

60.85M(98.26%)

61.06M(98.17%)

--(--)

Drug Products

325.00K(0.47%)

46.00K(0.05%)

2.34M(2.80%)

1.16M(1.59%)

1.08M(1.74%)

1.14M(1.83%)

--(--)

Concentrate Products –Product Sales – Point-in-time Over time

--(--)

58.78M(96.31%)

60.99M(96.22%)

Concentrate Products –License Fee – Point-in-time

--(--)

1.98M(3.24%)

2.12M(3.35%)

Drug Revenues-License Fee – Over time

--(--)

273.00K(0.45%)

273.00K(0.43%)

地区

营业收入

占比

年报

年报

单季报

United States

Rest of World

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

United States

60.36M(87.15%)

92.26M(90.90%)

74.34M(88.91%)

65.77M(90.32%)

55.39M(89.44%)

56.58M(90.97%)

54.52M(89.33%)

54.38M(85.80%)

Rest of World

8.90M(12.85%)

9.23M(9.10%)

9.27M(11.09%)

7.04M(9.68%)

6.54M(10.56%)

5.62M(9.03%)

6.51M(10.67%)

9.00M(14.20%)